28
Participants
Start Date
May 1, 2025
Primary Completion Date
December 30, 2025
Study Completion Date
December 30, 2025
Morning administration group of teriparatide
Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m. in the morning (Group A) and subcutaneous injection of 20 μg teriparatide at 20:00 p.m. in the evening (Group B).
Evening administration group of teriparatide
Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m. in the morning (Group A) and subcutaneous injection of 20 μg teriparatide at 20:00 p.m. in the evening (Group B).
Peking University Third Hospital
OTHER